A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.

about

A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.

Item

http://www.wikidata.org/entity/Q55460770

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

A classification prognostic sc ...... ntiated neuroendocrine tumors.

@en

A classification prognostic sc ...... ntiated neuroendocrine tumors.

@nl

type

Item

label

A classification prognostic sc ...... ntiated neuroendocrine tumors.

@en

A classification prognostic sc ...... ntiated neuroendocrine tumors.

@nl

prefLabel

A classification prognostic sc ...... ntiated neuroendocrine tumors.

@en

A classification prognostic sc ...... ntiated neuroendocrine tumors.

@nl

P1476

A classification prognostic sc ...... entiated neuroendocrine tumors

@en

P2093

Annalisa Trama

http://www.w3.org/2001/XMLSchema#string

Antongiulio Faggiano

http://www.w3.org/2001/XMLSchema#string

Daniela Femia

http://www.w3.org/2001/XMLSchema#string

Dario Giuffrida

http://www.w3.org/2001/XMLSchema#string

Davide Campana

http://www.w3.org/2001/XMLSchema#string

Elizabeth Van Eycken

http://www.w3.org/2001/XMLSchema#string

Emilio Bajetta

http://www.w3.org/2001/XMLSchema#string

Fiona Dwane

http://www.w3.org/2001/XMLSchema#string

Francesca Spada

http://www.w3.org/2001/XMLSchema#string

Francesco Panzuto

http://www.w3.org/2001/XMLSchema#string

P2860

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Everolimus for advanced pancreatic neuroendocrine tumors.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Epidemiology of gastroenteropancreatic neuroendocrine tumours.

Recommendations for management of patients with neuroendocrine liver metastases.

P304

607-618

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/ERC-17-0489

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29559553

http://www.w3.org/2001/XMLSchema#string

P932

5920017

http://www.w3.org/2001/XMLSchema#string